4 Healthcare Stock Stories For a Midweek Investment Checkup

Merck & Co. (NYSE:MRK): Closing price $47.77

On Wednesday, Merck announced that its board has declared a quarterly dividend of 43 cents per share on its common stock for the fourth quarter of 2013. Payment will be made on October 7 to stockholders of record as of the close on September 16.

Are these stocks a buy or sell? Let us help you decide. MRK

Mylan Inc. (NASDAQ: MYL): Closing price $32.38

Mylan said Wednesday that subsidiary Mylan Pharmaceuticals Inc. has reached an agreement with OSI, Pfizer and Genentech which will settle patent litigation connected with Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg. This medication represents the generic version of Tarceva, and is indicated in combination with gemcitabine for the first-line treatment of patients having locally advanced, unresectable or metastatic pancreatic cancer. Through the terms, pending litigation will be dismissed. All other terms and conditions of the accord are confidential, and the deal itself is subject to review by the Department of Justice and the Federal Trade Commission.

Are these stocks a buy or sell? Let us help you decide. MYL

Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR): Closing price $46.15

Questcor said Wednesday that patient screening will begin in connection with its Phase 2 Study to examine the safety and tolerability of H.P. Acthar Gel (repository corticotropin injection) in patients suffering from Amyotrophic Lateral Sclerosis. The condition is often known as Lou Gehrig’s disease, and is a progressive, degenerative disease affecting motor neurons. According to the ALS Association, the average life expectancy from the time of diagnosis for someone affected by this disorder is between two to five years. The study will attempt to enroll as many as 40 patients in an 8-week randomized, open-label trial designed to explore the safety and tolerability of four dosing regimens of Acthar.

Are these stocks a buy or sell? Let us help you decide. QCOR

Trovagene, Inc. (NASDAQ:TROV): Closing price $7.83

The developer of cell-free molecular diagnostics has announced the issuance of United States patent 8,486,626, for methods of detecting cell-free miRNA in urine and blood. The patent covers the detection and quantitation of microRNA, using a wide variety of technologies and platforms. MicroRNAs are known to play critical roles in cell development, along with several diseases, among which include cancer.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TROV

Don’t Miss: Are the Super Wealthy Buying Stocks Again?

More from The Cheat Sheet